Safa AR - Search Results

1

Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.

Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR. Rocha Lima CM, et al. Among authors: safa ar. Semin Oncol. 1999 Oct;26(5 Suppl 16):43-50; discussion 71-2. Semin Oncol. 1999. PMID: 10585008 Review.

2

Irinotecan and gemcitabine in patients with solid tumors: phase I trial.

Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Green MR. Rocha Lima CM, et al. Among authors: safa ar. Oncology (Williston Park). 2002 May;16(5 Suppl 5):19-24. Oncology (Williston Park). 2002. PMID: 12109801 Free article. Clinical Trial.

3

Irinotecan in the management of patients with pancreatic cancer.

Green MR, Harper M, Safa A, Sherman CA, Mushtaq CM, Bahadori H, Brescia FJ, Rocha Lima CM. Green MR, et al. Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):31-3. Oncology (Williston Park). 2000. PMID: 11200146 Free article. Review.

4

Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines.

Bahadori HR, Rocha Lima CM, Green MR, Safa AR. Bahadori HR, et al. Among authors: safa ar. Anticancer Res. 1999 Nov-Dec;19(6B):5423-8. Anticancer Res. 1999. PMID: 10697572

5

Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines.

Ogretmen B, Bahadori HR, McCauley MD, Boylan A, Green MR, Safa AR. Ogretmen B, et al. Among authors: safa ar. Int J Cancer. 1998 Mar 2;75(5):757-61. doi: 10.1002/(sici)1097-0215(19980302)75:5<757::aid-ijc15>3.0.co;2-3. Int J Cancer. 1998. PMID: 9495245

6

Lack of correlation of MRP and gamma-glutamylcysteine synthetase overexpression with doxorubicin resistance due to increased apoptosis in SV40 large T-antigen-transformed human mesothelial cells.

Ogretmen B, Bahadori H, McCauley M, Boylan A, Green M, Safa AR. Ogretmen B, et al. Among authors: safa ar. Cancer Chemother Pharmacol. 1998;42(6):441-6. doi: 10.1007/s002800050843. Cancer Chemother Pharmacol. 1998. PMID: 9788569

7

Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia.

Ogretmen B, Barredo JC, Safa AR. Ogretmen B, et al. Among authors: safa ar. J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):45-9. doi: 10.1097/00043426-200001000-00009. J Pediatr Hematol Oncol. 2000. PMID: 10695821

8

Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.

Ogretmen B, McCauley MD, Safa AR. Ogretmen B, et al. Among authors: safa ar. Biochemistry. 1998 Aug 18;37(33):11679-91. doi: 10.1021/bi980573c. Biochemistry. 1998. PMID: 9709006

9

A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.

Robertson MJ, Stamatkin CW, Pelloso D, Weisenbach J, Prasad NK, Safa AR. Robertson MJ, et al. Among authors: safa ar. J Immunother. 2018 Apr;41(3):151-157. doi: 10.1097/CJI.0000000000000220. J Immunother. 2018. PMID: 29517616 Free PMC article. Clinical Trial.

10

Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region.

Ogretmen B, Safa AR. Ogretmen B, et al. Among authors: safa ar. Biochemistry. 1999 Feb 16;38(7):2189-99. doi: 10.1021/bi982236+. Biochemistry. 1999. PMID: 10026303

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters